Form 4: Myriad Genetics CEO Samraat Raha Increases Stake

Myriad Genetics President and CEO Samraat S. Raha acquired 3,542 shares of common stock through the company's employee stock purchase plan.

Summary

• Samraat S. Raha, President and CEO of Myriad Genetics, acquired 3,542 shares of common stock.
• The transaction occurred on June 11, 2026, at a price of $3.936 per share.
• Following this transaction, the reporting person's total beneficial ownership increased to 1,068,083 shares.
• The acquisition was executed under the Issuer's Amended and Restated 2012 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding executive equity ownership.

Positives

• Insider acquisition of shares demonstrates management's commitment to the company's long-term equity value.
• The transaction was conducted through a standard, pre-approved employee stock purchase plan.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider acquisitions via employee stock purchase plans are standard corporate governance practices and generally reflect internal confidence rather than a reaction to specific market events.

Comparison to Industry Standards

• The acquisition follows standard regulatory compliance for executive equity participation.
• The use of an Employee Stock Purchase Plan (ESPP) is a common industry practice for aligning executive interests with shareholders.

Stakeholder Impact

• Shareholders may view the CEO's increased equity stake as a positive signal of alignment.

Key Dates

Keywords

Myriad Genetics, MYGN, Insider Trading, Form 4, Stock Purchase Plan, Executive Compensation